Mobile

Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment at 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, double...

Update Il y a 4 ans
Reference: EUCTR2008-003421-17

Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment at 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, double-blind, placebo-controlled, with paroxetine (20 mg/day with potential progressive blinded adjustment to 40 mg/day) as validator, 3-arm parallel groups, international multicenter study

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To confirm the efficacy of agomelatine (25-50 mg/day p.o.) compared to placebo after a 12-week orally treatment in non-depressed out-patients suffering from Generalized Anxiety Disorder.

Inclusion criteria

  • Generalized Anxiety Disorder

Links